Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions: A Systematic Review and Meta-analysis.

Background High-risk human papillomavirus (hrHPV) testing to triage women with minor cervical lesions generates many referrals. Purpose To evaluate the accuracy of genotyping for HPV types 16 and 18 and its utility as a second triage step after hrHPV testing in women with minor cervical lesions. Data Sources Searches of 4 bibliographic databases, without language restrictions, from 1 January 1999 to 1 February 2016. Study Selection Studies involving women with atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesions (LSIL) who were triaged with tests for hrHPV and HPV 16/18 to find cervical intraepithelial neoplasia (grade ≥2 [CIN2+] or grade ≥3 [CIN3+]). Data Extraction Independent study selection, extraction of data, and quality assessment by 2 reviewers. Data Synthesis Twenty-four moderate- to good-quality studies involving 8587 women with ASC-US and 5284 with LSIL were found. The pooled sensitivity of HPV 16/18 genotyping for CIN3+ was about 70% for women with either ASC-US or LSIL. The pooled specificity (with a threshold of grade <2 CIN) was 83% (95% CI, 80% to 86%) for women with ASC-US and 76% (CI, 74% to 79%) for those with LSIL. The average risk for CIN3+ was 17% and 19% in HPV 16/18-positive women with ASC-US and LSIL, respectively, and was 5% in hrHPV-positive but HPV 16/18-negative women with either ASC-US or LSIL. Limitation Methodological and technical heterogeneity among studies; insufficient data to assess accuracy of separate assays. Conclusion Testing for HPV 16/18 to triage women with minor abnormal cytology is poorly sensitive but may be useful as a second triage test after hrHPV testing, with direct referral if the woman is positive for HPV 16/18. Whether colposcopy or repeated testing is recommended for hrHPV-positive but HPV 16/18-negative women depends on local decision thresholds that can be derived from pretest-posttest probability plots. Primary Funding Source 7th Framework Programme of the European Commission.

[1]  J. Srisomboon,et al.  High performance of combined HPV testing and genotyping for HPV16/18/52/58 in triaging women with minor cervical cytological abnormalities in northern Thailand , 2016, Journal of medical virology.

[2]  M. Schiffman,et al.  p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women. , 2015, Journal of the National Cancer Institute.

[3]  Y. Qiao,et al.  Human Papillomavirus Genotyping to Predict the Risk of Cervical Precancerous Lesions or Cancer in Women with Minor Abnormal Cytology in China , 2015, Acta Cytologica.

[4]  H. Kuramoto,et al.  Human Papillomavirus Test for Triage of Japanese Women With Low-Grade Squamous Intraepithelial Lesions , 2015, Reproductive Sciences.

[5]  M. Noguchi,et al.  HPV genotyping for triage of women with abnormal cervical cancer screening results: a multicenter prospective study , 2015, International Journal of Clinical Oncology.

[6]  M. Leeflang,et al.  Cochrane diagnostic test accuracy reviews , 2013, Systematic Reviews.

[7]  Â. Pista,et al.  Use of the NucliSENS EasyQ HPV assay in the management of cervical intraepithelial neoplasia , 2013, Journal of medical virology.

[8]  C. Wheeler,et al.  Risk of Precancer Determined by HPV Genotype Combinations in Women with Minor Cytologic Abnormalities , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[9]  M. Leeflang,et al.  Empirical Evidence of the Importance of Comparative Studies of Diagnostic Test Accuracy , 2013, Annals of Internal Medicine.

[10]  M. Schiffman,et al.  Benchmarking CIN 3+ Risk as the Basis for Incorporating HPV and Pap Cotesting into Cervical Screening and Management Guidelines , 2013, Journal of lower genital tract disease.

[11]  Marc Arbyn,et al.  Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. , 2013, The Cochrane database of systematic reviews.

[12]  J. Cuzick,et al.  Human papillomavirus testing for triage of women with low‐grade squamous intraepithelial lesions , 2013, International journal of cancer.

[13]  Julian Peto,et al.  Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. , 2012, Vaccine.

[14]  A. Spathis,et al.  mRNA and DNA Detection of Human Papillomaviruses in Women of All Ages Attending Two Colposcopy Clinics , 2012, PloS one.

[15]  K. Seow,et al.  Human papillomavirus genotyping as a predictor of high‐grade cervical dysplasia in women with mildly cytologic abnormalities: A two‐year follow‐up report , 2012, Diagnostic cytopathology.

[16]  E. Pescarmona,et al.  p16/Ki-67 dual staining in cervico-vaginal cytology: correlation with histology, Human Papillomavirus detection and genotyping in women undergoing colposcopy. , 2012, Gynecologic oncology.

[17]  Roy Zhang,et al.  Performance of p16/Ki-67 Immunostaining to Detect Cervical Cancer Precursors in a Colposcopy Referral Population , 2012, Clinical Cancer Research.

[18]  M. Schiffman,et al.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer , 2012 .

[19]  J. Cuzick,et al.  Comparison of Seven Tests for High-Grade Cervical Intraepithelial Neoplasia in Women with Abnormal Smears: the Predictors 2 Study , 2012, Journal of Clinical Microbiology.

[20]  D. Provencher,et al.  Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undetermined Significance with cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of High-Grade Lesions of the Uterine Cervix , 2012, Journal of Clinical Microbiology.

[21]  O. G. Wong,et al.  Efficacy of Abbott RealTime High Risk HPV test in evaluation of atypical squamous cells of undetermined significance from an Asian screening population. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[22]  Y. Liu,et al.  A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid capture 2 and Cervista from the SHENCCAST II Study. , 2011, American journal of clinical pathology.

[23]  T. Wright,et al.  High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. , 2011, American journal of clinical pathology.

[24]  J. Bogers,et al.  BD-ProExC as Adjunct Molecular Marker for Improved Detection of CIN2+ after HPV Primary Screening , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[25]  A. Agostini,et al.  Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[26]  M. Einstein,et al.  Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. , 2010, Gynecologic oncology.

[27]  N. Segnan,et al.  European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition—Summary Document , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Penny Whiting,et al.  Metandi: Meta-analysis of Diagnostic Accuracy Using Hierarchical Logistic Regression , 2009 .

[29]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, PLoS medicine.

[30]  K. Abravaya,et al.  Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[31]  S. Bose,et al.  Invader human papillomavirus (HPV) type 16 and 18 assays as adjuncts to HPV screening of cervical papanicolaou smears with atypical squamous cells of undetermined significance , 2009, Cancer.

[32]  J. Dillner,et al.  Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate , 2009, Journal of cellular and molecular medicine.

[33]  J. Cuzick,et al.  Comparison of Predictors for High-Grade Cervical Intraepithelial Neoplasia in Women with Abnormal Smears , 2008, Cancer Epidemiology Biomarkers & Prevention.

[34]  A. Hjerpe,et al.  Human papillomavirus ‘reflex’ testing as a screening method in cases of minor cytological abnormalities , 2008, British Journal of Cancer.

[35]  K. Syrjänen,et al.  Linear array genotyping and hybrid capture II assay in detecting human papillomavirus genotypes in women referred for colposcopy due to abnormal Papanicolaou smear , 2008, International journal of STD & AIDS.

[36]  N. Sneige,et al.  Human papillomavirus genotyping for the eight oncogenic types can improve specificity of HPV testing in women with mildly abnormal Pap results , 2008, Modern Pathology.

[37]  Gordon H Guyatt,et al.  GRADE: grading quality of evidence and strength of recommendations for diagnostic tests and strategies , 2008, BMJ : British Medical Journal.

[38]  Roger M Harbord,et al.  A unification of models for meta-analysis of diagnostic accuracy studies. , 2007, Biostatistics.

[39]  J. Dillner,et al.  Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. , 2006, Vaccine.

[40]  M. Schiffman,et al.  Determinants of human papillomavirus‐negative, low‐grade squamous intraepithelial lesions in the atypical squamous cells of undetermined significance/low‐grade squamous intraepithelial lesions triage study (ALTS) , 2005, Cancer.

[41]  Jonathan J Deeks,et al.  The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. , 2005, Journal of clinical epidemiology.

[42]  Joakim Dillner,et al.  Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. , 2004, Journal of the National Cancer Institute.

[43]  Joan L. Walker A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. , 2003, American journal of obstetrics and gynecology.

[44]  M. Sherman,et al.  The 2001 Bethesda system: Terminology for reporting results of cervical cytology , 2002 .

[45]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[46]  A. Miller,et al.  Natural history of dysplasia of the uterine cervix. , 1999, Journal of the National Cancer Institute.

[47]  D. Evans,et al.  Terminology in gynaecological cytopathology: report of the Working Party of The British Society for Clinical Cytology , 1986, Journal of clinical pathology.

[48]  小島原典子,et al.  診断精度研究のバイアスリスク評価ツールQUADAS-2:a Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies 2 の活用 , 2014 .

[49]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Journal of clinical epidemiology.

[50]  Gerta Rucker,et al.  Bmc Medical Research Methodology Open Access the Relationship between Quality of Research and Citation Frequency , 2006 .